Recent Blog Articles
Some men whose prostate cancer progresses can safely delay treatment
Heart-healthy habits for children and teens lengthen lives
Monkeypox: An unfamiliar virus spreading fast — sound familiar?
Diabetes: Does a long-term study reinforce or change approaches to prevention?
War anxiety: How to cope
Can we prevent depression in older adults by treating insomnia?
Want to try veganism? Here's how to get started
Vitamin B6 flies under the radar: Are you getting enough?
The formula shortage is hurting families: What parents should know and do
Gyn Care 101: What to know about seeing a gynecologist
In the journals: The antidepressant citalopram cuts hot flash severity and frequency
As many of us know firsthand, hot flashes can be a bothersome symptom of declining estrogen levels at menopause as well as a common side effect of breast cancer treatment. For most women, hot flashes are transient and manageable, but for others, they're a daily (and sometimes nightly) burden that can persist for years, disrupting sleep and eroding quality of life. Estrogen therapy provides the most effective relief for hot flashes, but it's recommended only for short-term treatment of menopausal symptoms, and most women who've had breast cancer can't take it at all.
In recent years, randomized trials have shown that certain antidepressants can reduce hot flashes by 50% or more. These include paroxetine (Paxil) and fluoxetine (Prozac), which are selective serotonin reuptake inhibitors (SSRIs), and venlafaxine (Effexor), a serotonin-norepinephrine reuptake inhibitor (SNRI). However, paroxetine and fluoxetine have been found to greatly reduce the effectiveness of tamoxifen (Nolvadex), which is commonly used to reduce the likelihood of recurrence in women being treated for early-stage hormone receptor–positive breast cancer. Now, a randomized controlled trial has shown that citalopram (Celexa), an SSRI with little effect on tamoxifen metabolism, cuts the frequency and severity of hot flashes by at least 50% in postmenopausal women. Results were published in the July 10, 2010, issue of the Journal of Clinical Oncology.
To continue reading this article, you must log in.
Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.
- Research health conditions
- Check your symptoms
- Prepare for a doctor's visit or test
- Find the best treatments and procedures for you
- Explore options for better nutrition and exercise
I'd like to receive access to Harvard Health Online for only $4.99 a month.Sign Me Up
Already a member? Login ».
As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles.
No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.
Free Healthbeat Signup
Get the latest in health news delivered to your inbox!